GYRE

Gyre Therapeutics (GYRE)

About Gyre Therapeutics (GYRE)

Gyre Therapeutics, Inc. operates as a biopharmaceutical company. It is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis). The firm operates through the BC and Gyre segments. The company was founded on March 7, 1997 and is headquartered in San Diego, CA.

Details

Daily high

$6.51

Daily low

$6.21

Price at open

$6.28

52 Week High

$9.42

52 Week Low

$5.44

Market cap

694.6M

Dividend yield

0.00%

Volume

49,092

Avg. volume

52,823

P/E ratio

-80.08

Gyre Therapeutics News